ASCO: Array slips on MEK data, debt sale
This article was originally published in Scrip
Executive Summary
Array BioPharma closed down 1% at $5.78 per share and fell another 5.2% in after-hours trading to $5.48 on 3 June following news of mixed results for selumetinib and positive combination therapy data for MEK162. The company also disclosed a planned sale of up to $115 million in convertible debt.